The Pressure Infusion Bags Market size is expected to grow from USD 317.77 million in 2023 to USD 415.12 million by 2028, at a CAGR of 5.49% during the forecast period (2023-2028).
The COVID-19 pandemic had a significant impact on the market since the demand for pressure infusion bags increased considerably during the COVID-19 lockdown with the number of COVID-19 cases increasing at a faster rate with increased hospital emergency department admissions. For instance, according to an article published by PubMed in September 2021, a study was conducted in the United States which showed that COVID-19-related emergency visits increased for persons aged 0-4, 5-11, and 12-17 years, and hospital admissions of patients with confirmed COVID-19 increased for persons aged 0-17 years during 2021. The article also stated that the proportion of COVID-19 patients aged 0-17 years who were admitted to an ICU ranged from 20% and 18% during July and August 2021. Thus, the pressure infusion market was significantly impacted by the COVID-19 pandemic. However, as the pandemic has subsided currently, the studied market is expected to have stable during the forecast period of the study.
Certain factors that are driving the market growth include the rising prevalence of chronic diseases and surge in emergency transfusion cases and technological advancements, and increasing R&D initiatives. According to the data published by the Australian Institute of Health and Welfare in July 2022, it is estimated that almost half (47%, or 11.6 million) of Australians have one or more common chronic health conditions (including diabetes, cancer, mental and behavioral conditions, and chronic kidney disease) in 2021. Therefore, as the number of chronic disease patients increases, the demand for infusion bags will increase over the projected period.
Moreover, according to an article published by JAMA Network in June 2022, a study was conducted in Sweden which showed that the prevalence and burden of atherosclerosis in the general population have been very high, and the estimated prevalence of poly-vascular atherosclerosis ranged from 3% to 42%. The treatment of diseases like atherosclerosis includes surgical procedures, which will lead to more usage of pressure infusion bags.
The pressure infuser has also become a necessary component of various medical procedures such as rapid infusion of blood, blood products, blood expanders, IV solutions, and invasive pressure monitoring procedures. For instance, according to an article updated by NCBI in August 2022, in an acute setting, where the clinical situation might indicate a rapid infusion of crystalloid fluids, pressure infusion bags are used to achieve a higher infusion rate.
Thus, all aforementioned factors, such as the increasing number of chronic diseases and the technological advancement in pressure infusion bags, are expected to boost the market over the forecast period. However, the lack of skilled professionals is expected to impede the growth of the market.
Hypovolemia is a condition that is commonly caused by dysfunction of various organs, such as congestive heart failure or kidney failure. If the hypovolemia is severe or persists over a long period of time, the compensatory changes in cardiac function may deteriorate into progressive cardiac failure. Hence, to avoid hypovolemia conditions in heart failure patients, pressure infusion bags are used, which is expected to increase the demand for the market studied. For instance, according to the Heart and Circulatory Disease Statistics 2023, 936,556 patients were admitted to NHS hospitals in England for heart and circulatory diseases during 2021-2022. This was an increase from 807,074 patients in 2020-2021. Hence, the increase in cardiovascular disease admissions in hospitals is expected to increase the demand for blood and drug infusions, thereby contributing to the segment's growth over the forecast period.
Additionally, the increase in strategic activities by key players like blood and drug infusion IV bag launches, collaboration, and partnerships to increase the availability of pressure infusion bags across various regions are expected to bolster market growth over the forecast period. For instance, in June 2022, Gufic Biosciences launched dual-chamber IV bags for drug delivery in India. Gufic Biosciences collaborated with its French counterpart to manufacture the IV bag in India.
Hence, with the growing prevalence of chronic diseases such as cardiovascular diseases and cancer and strategic activities by the key players, the studied segment is expected to witness growth over the forecast period.
According to the 2023 statistics published by the American Cancer Society, about 1.95 million new cancer cases are expected to be diagnosed in the United States in 2023, as compared to 1.91 million cases in 2022. Cancer treatment deprives the human body of nutrition and affects the body by causing ulcers, gastrointestinal dysfunction, and physical blockages, which increases the demand for delivering parenteral nutrition to patients. This is expected to fuel demand for pressure infusion bags, which are used to pressurize sterile parenteral fluids to patients, boosting market expansion.
Additionally, complex procedures, such as orthopedic replacements or thoracic surgery, performed in the country are expected to increase the demand for pressure infusion bags since intravenous medications are mostly given through pressure infusion bags. For instance, according to the data published by the Canadian Institute for Health Information in December 2022, about 700 outpatient hip and knee replacements were performed in Canada during 2021-2022. Thus, a high number of replacement procedures is expected to fuel market growth over the forecast period. Furthermore, according to the data from the National Safety Council in 2021, an estimated 3.2 million people were treated in emergency departments for injuries involving sports and recreational equipment in the United States in 2021. The activities most frequently associated with injuries are exercise, cycling, and basketball. Therefore, the rise in the number of injuries associated with these types of activities is also expected to increase the adoption of pressure infusion bags.
Additionally, the increasing focus of the companies on adopting various key strategic initiatives such as acquisitions, partnerships, and other initiatives is expected to increase the number of infusion bags in the market, thereby propelling market growth. For instance, in January 2022, ICU Medical Inc. completed its acquisition of Smiths Medical from Smiths Group PLC. The Smiths Medical business includes syringes and ambulatory infusion devices (including pressure infusion bags), vascular access, and vital care products.
Hence, all the aforementioned factors, such as the increasing number of chronic diseases and their requirement for surgeries, coupled with strategic acquisitions by the key players, are expected to boost the growth of the market in the North America Region.
The COVID-19 pandemic had a significant impact on the market since the demand for pressure infusion bags increased considerably during the COVID-19 lockdown with the number of COVID-19 cases increasing at a faster rate with increased hospital emergency department admissions. For instance, according to an article published by PubMed in September 2021, a study was conducted in the United States which showed that COVID-19-related emergency visits increased for persons aged 0-4, 5-11, and 12-17 years, and hospital admissions of patients with confirmed COVID-19 increased for persons aged 0-17 years during 2021. The article also stated that the proportion of COVID-19 patients aged 0-17 years who were admitted to an ICU ranged from 20% and 18% during July and August 2021. Thus, the pressure infusion market was significantly impacted by the COVID-19 pandemic. However, as the pandemic has subsided currently, the studied market is expected to have stable during the forecast period of the study.
Certain factors that are driving the market growth include the rising prevalence of chronic diseases and surge in emergency transfusion cases and technological advancements, and increasing R&D initiatives. According to the data published by the Australian Institute of Health and Welfare in July 2022, it is estimated that almost half (47%, or 11.6 million) of Australians have one or more common chronic health conditions (including diabetes, cancer, mental and behavioral conditions, and chronic kidney disease) in 2021. Therefore, as the number of chronic disease patients increases, the demand for infusion bags will increase over the projected period.
Moreover, according to an article published by JAMA Network in June 2022, a study was conducted in Sweden which showed that the prevalence and burden of atherosclerosis in the general population have been very high, and the estimated prevalence of poly-vascular atherosclerosis ranged from 3% to 42%. The treatment of diseases like atherosclerosis includes surgical procedures, which will lead to more usage of pressure infusion bags.
The pressure infuser has also become a necessary component of various medical procedures such as rapid infusion of blood, blood products, blood expanders, IV solutions, and invasive pressure monitoring procedures. For instance, according to an article updated by NCBI in August 2022, in an acute setting, where the clinical situation might indicate a rapid infusion of crystalloid fluids, pressure infusion bags are used to achieve a higher infusion rate.
Thus, all aforementioned factors, such as the increasing number of chronic diseases and the technological advancement in pressure infusion bags, are expected to boost the market over the forecast period. However, the lack of skilled professionals is expected to impede the growth of the market.
Pressure Infusion Bags Market Trends
Blood and Drug Infusion is Expected to Show Lucrative Growth in the Pressure Infusion Bags Market Over the Forecast Period
Blood and drug infusions are carried out whenever any surgical procedure takes place that involves the loss of blood or the need for drug injection through infusion bags. As the prevalence of chronic diseases is rising worldwide, the treatment of various chronic diseases has been increasingly prioritized by the global health community or governments, even in low- and middle-income countries. As a result, the demand for rapid fluid transfusion has risen significantly in order to address the global disease burden, thus leading to a rise in the utilization and adoption of pressure infusion bags.Hypovolemia is a condition that is commonly caused by dysfunction of various organs, such as congestive heart failure or kidney failure. If the hypovolemia is severe or persists over a long period of time, the compensatory changes in cardiac function may deteriorate into progressive cardiac failure. Hence, to avoid hypovolemia conditions in heart failure patients, pressure infusion bags are used, which is expected to increase the demand for the market studied. For instance, according to the Heart and Circulatory Disease Statistics 2023, 936,556 patients were admitted to NHS hospitals in England for heart and circulatory diseases during 2021-2022. This was an increase from 807,074 patients in 2020-2021. Hence, the increase in cardiovascular disease admissions in hospitals is expected to increase the demand for blood and drug infusions, thereby contributing to the segment's growth over the forecast period.
Additionally, the increase in strategic activities by key players like blood and drug infusion IV bag launches, collaboration, and partnerships to increase the availability of pressure infusion bags across various regions are expected to bolster market growth over the forecast period. For instance, in June 2022, Gufic Biosciences launched dual-chamber IV bags for drug delivery in India. Gufic Biosciences collaborated with its French counterpart to manufacture the IV bag in India.
Hence, with the growing prevalence of chronic diseases such as cardiovascular diseases and cancer and strategic activities by the key players, the studied segment is expected to witness growth over the forecast period.
North America is Expected to Hold a Significant Share in the Pressure Infusion Bags Market Over the Forecast Period
North America is expected to hold a significant share of the pressure infusion bags market, primarily due to the high prevalence of chronic diseases, high healthcare expenditures, and the increase in surgical treatments for chronic diseases. In addition, the rapid advancements in pressure infusion systems are also expected to fuel market growth in the North American region.According to the 2023 statistics published by the American Cancer Society, about 1.95 million new cancer cases are expected to be diagnosed in the United States in 2023, as compared to 1.91 million cases in 2022. Cancer treatment deprives the human body of nutrition and affects the body by causing ulcers, gastrointestinal dysfunction, and physical blockages, which increases the demand for delivering parenteral nutrition to patients. This is expected to fuel demand for pressure infusion bags, which are used to pressurize sterile parenteral fluids to patients, boosting market expansion.
Additionally, complex procedures, such as orthopedic replacements or thoracic surgery, performed in the country are expected to increase the demand for pressure infusion bags since intravenous medications are mostly given through pressure infusion bags. For instance, according to the data published by the Canadian Institute for Health Information in December 2022, about 700 outpatient hip and knee replacements were performed in Canada during 2021-2022. Thus, a high number of replacement procedures is expected to fuel market growth over the forecast period. Furthermore, according to the data from the National Safety Council in 2021, an estimated 3.2 million people were treated in emergency departments for injuries involving sports and recreational equipment in the United States in 2021. The activities most frequently associated with injuries are exercise, cycling, and basketball. Therefore, the rise in the number of injuries associated with these types of activities is also expected to increase the adoption of pressure infusion bags.
Additionally, the increasing focus of the companies on adopting various key strategic initiatives such as acquisitions, partnerships, and other initiatives is expected to increase the number of infusion bags in the market, thereby propelling market growth. For instance, in January 2022, ICU Medical Inc. completed its acquisition of Smiths Medical from Smiths Group PLC. The Smiths Medical business includes syringes and ambulatory infusion devices (including pressure infusion bags), vascular access, and vital care products.
Hence, all the aforementioned factors, such as the increasing number of chronic diseases and their requirement for surgeries, coupled with strategic acquisitions by the key players, are expected to boost the growth of the market in the North America Region.
Pressure Infusion Bags Industry Overview
The pressure infusion bags market is moderately competitive and consists of a few major players. Market players are focusing on geographic expansions, new product launches, and the development of new products. Companies like Eakin Healthcare Group (Armstrong Medical Inc.), Merit Medical System, ICU Medical Inc., Tapmedic LLC, and SunMed hold a substantial market share in the market.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Eakin Healthcare Group (Armstrong Medical Inc.)
- Ecomed
- Merit Medical Systems
- Sarstedt AG & Co. KG
- ICU Medical Inc.
- SunMed
- Tapmedic LLC
- VBM Medizintechnik GmbH
- Spengler SAS
- Fairmont Medical
- Biegler GmbH
Methodology
LOADING...
